COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04762680

Not reported

Not reported

2021-02-21

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: -aged 18 years or older on the day of inclusion. - -a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female mut be post-menopausal for at least 1 year or surgically sterile. or is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination (ie, second dose of primary series or booster injection). a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention. - -informed consent form has been signed and dated. able to attend all scheduled visits and to comply with all study procedures. sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies (original phase 2 cohort). for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count > 200/mm3. does not intend to receive an authorized/approved covid-19 vaccine from first vaccination to 3 weeks after the second vaccination despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. supplemental cohorts: for participants originally enrolled in the phase ii cohort of the study, informed consent has to be signed and dated for transitioning to supplemental cohort 2. supplemental cohorts, booster arms: received a complete primary vaccination series with an authorized/conditionally approved mrna covid-19 vaccine (mrna-1273 [moderna] or bnt162b2 [pfizer/biontech]) or adenovirus-vectored covid-19 vaccine (chadox1 ncov-19 [oxford university/astrazeneca] or ad26.cov2.s [j&j/janssen]), with the last dose administered a minimum of 4 months prior to inclusion but not longer than 10 months prior to inclusion.

-known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on investigator or designee's judgment. self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator's judgment. bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator's judgment. unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. receipt of solid-organ or bone marrow transplants in the past 180 days. receipt of anti-cancer chemotherapy in the last 90 days. receipt of immunoglobulins, blood, or blood-derived products in the past 3 months. moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°c [≥ 100.4°f]). a prospective participant should not be included in the trial until the condition has resolved or the febrile event has subsided. receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. applicable to original phase ii cohort, supplemental cohort 1 and cohort 2 comparator group: prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome [mers-cov]). participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study trial period in another clinical study investigating a vaccine, drug, medical device, or medical procedure. exclusion criterion for the supplemental cohort 1 and cohort 2 comparator group: positive rapid diagnostic test for sars-cov-2 antibodies at time of enrollment. exclusion criterion for participants in supplemental cohort 2 who were primed as participant in the original phase ii cohort of the present study: receipt of authorized/conditionally approved covid-19 vaccine after enrollment in original phase 2 cohort. exclusion criterion for all booster groups: documented virologically-confirmed sars-cov-2 infection (by naat) after first dose of primary immunization.

12

Sanofi Pasteur, a Sanofi Company

18

100

Australia;France;Honduras;New Zealand;Spain;United Kingdom;United States

Healthy volunteers

N/A

3385

2-fold rise and 4-fold-rise in neutralization antibody titer;Neutralizing antibody titer at Day 1;Neutralizing antibody titer at Day 15 (post-booster injection);Neutralizing antibody titer at Day 1 (pre-booster injection);Neutralizing antibody titer at Day 36;Neutralizing antibody titer at Day 36 (Cohorts 1 and 2 Comparator Group);Neutralizing antibody titer fold-rise post-vaccination;Presence of adverse events of special interest;Presence of immediate adverse events;Presence of medically-attended adverse events;Presence of serious adverse events;Presence of solicited injection site or systemic reactions;Presence of unsolicited adverse events;Responders, as determined by neutralizing antibody titers at Day 36;Responders, as determined by neutralizing antibody titers at Day 36 (Cohorts 1 and 2 Comparator Group)

None

Phase 2/Phase 3

[{"arm_notes": "Formulation 1", "treatment_id": 1154, "treatment_name": "Sars-cov-2 recombinant protein vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Formulation 2", "treatment_id": 1154, "treatment_name": "Sars-cov-2 recombinant protein vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Formulation 3", "treatment_id": 1154, "treatment_name": "Sars-cov-2 recombinant protein vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nan", "treatment_id": 1935, "treatment_name": "As03 adjuvant+sars-cov-2 recombinant protein vaccine monovalent (b.1.351)", "treatment_type": "Adjuvant+protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Dosage 1", "treatment_id": 1936, "treatment_name": "As03 adjuvant+sars-cov-2 recombinant protein vaccine monovalent (d614)", "treatment_type": "Adjuvant+protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Dosage 2", "treatment_id": 1936, "treatment_name": "As03 adjuvant+sars-cov-2 recombinant protein vaccine monovalent (d614)", "treatment_type": "Adjuvant+protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "nan", "treatment_id": 1934, "treatment_name": "Sars-cov-2 recombinant protein vaccine bivalent (d614+b.1.351)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "previously unvaccinated, na\u00efve participants", "treatment_id": 1932, "treatment_name": "Sars-cov-2 recombinant protein vaccine monovalent (d614)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "prior with an authorized mRNA COVID-19", "treatment_id": 1933, "treatment_name": "Sars-cov-2 recombinant protein vaccine monovalent (b.1.351)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "prior with an authorized mRNA COVID-19", "treatment_id": 1933, "treatment_name": "Sars-cov-2 recombinant protein vaccine monovalent (b.1.351)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "prior with an authorized mRNA COVID-19", "treatment_id": 1933, "treatment_name": "Sars-cov-2 recombinant protein vaccine monovalent (b.1.351)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "prior with an authorized mRNA COVID-19", "treatment_id": 1933, "treatment_name": "Sars-cov-2 recombinant protein vaccine monovalent (b.1.351)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]